CRS | CERES Regulatory Services

Get in Touch
Logo-CERES-Regulatory ceres-logo, logo-ceres, logo
Menu
Book a Call
Logo-CERES regulatory Services, CRS-Logo, logo-CRS
Menu
Get in Touch

Category: Clinical Studies

The Mayzent Resubmission Journey: From FDA CRL to Approval 

Hello Regulatory Scientists, Today, let’s dive into the journey of Mayzent (siponimod) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Mayzent (siponimod) Mechanism of Action: Sphingosine-1-phosphate receptor modulator, which helps reduce the number of lymphocytes that can reach the central nervous system Indication: Treatment of relapsing forms of multiple sclerosis (MS) Initial Submission Date: February 2018 The Complete Response Letter (CRL) CRL Date: June 2018 CRL Concerns: Clinical Data Requirements: The FDA requested more detailed analyses of the clinical data to better understand the efficacy of the drug across different patient subgroups. Safety Profile: Concerns related to the drug’s long-term safety profile, including cardiovascular risks and potential adverse effects on liver function. Manufacturing Process: Issues related to the consistency and quality of the drug’s manufacturing process. Resubmission Strategy Novartis, the company behind Mayzent, implemented a comprehensive strategy to address the FDA’s concerns: Extended Data Analysis: Conducted additional analyses of the clinical trial data to provide a clearer picture of the drug’s efficacy across various patient subgroups. Enhanced Safety Monitoring: Provided additional data on the long-term safety profile, focusing on cardiovascular health and liver function. Improved Manufacturing Processes: Implemented improvements in the manufacturing process to ensure consistency and quality. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. Resubmission Date: October 2018 Outcome Approval Date: March 2019 Mayzent was approved for the treatment of relapsing forms of multiple sclerosis, providing a new option for patients with this condition. Lessons Learned The journey of Mayzent from CRL to approval highlights several key lessons for drug developers: Thorough Data Analysis: Providing detailed and comprehensive data analyses is crucial to demonstrate a drug’s efficacy across different patient subgroups. Robust Safety Monitoring: Ensuring a thorough understanding and communication of the drug’s long-term safety profile can help mitigate regulatory concerns. Improved Manufacturing Standards: Ensuring the quality and consistency of the manufacturing process is essential for regulatory approval. Effective Use of Advisory Committees: Leveraging advisory committees can provide valuable feedback and support the resubmission process. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. Relevance for Current Drug Developers For companies developing drugs today, the Mayzent case underscores the importance of strategic planning and meticulous data analysis in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including clinical data and manufacturing processes, meet FDA standards. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. By learning from the Mayzent resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. Stay diligent and strategic, CERES Regulatory Services

Hello Regulatory Scientists,  Today, let’s dive into the journey of Mayzent (siponimod) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today.  Regulatory History and Initial Submission  Drug: Mayzent (siponimod) Mechanism of Action: Sphingosine-1-phosphate receptor modulator, which helps reduce […]

The Imfinzi Resubmission Journey: From FDA CRL to Approval 

FDA CRL Wordcloud7

Hello Regulatory Scientists,  Today, let’s delve into the journey of Imfinzi (durvalumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today.  Regulatory History and Initial Submission  Drug: Imfinzi (durvalumab) Mechanism of Action: PD-L1 inhibitor, which helps the immune […]

Navigating the FDA Complete Response Letter: The Xeljanz Resubmission Journey

darkhorse consulting

Hello Regulatory Scientists, Today, let’s dive into the fascinating journey of Xeljanz (tofacitinib) from receiving an FDA Complete Response Letter (CRL) to eventual approval. This case study not only sheds light on the intricacies of regulatory processes but also offers valuable lessons for those developing drugs today. Regulatory History and Initial Submission Drug: Xeljanz (tofacitinib) […]

The Opdivo Resubmission Journey: From FDA CRL to Approval

best life science consulting firms

Hello Regulatory Scientists, Today, let’s explore the journey of Opdivo (nivolumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Opdivo (nivolumab) Mechanism of Action: PD-1 inhibitor, which helps the immune […]

The Zydelig Resubmission Journey: Navigating the Path to FDA Approval

darkhorse consulting

Hello Regulatory Scientists, Today, let’s explore the journey of Zydelig (idelalisib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case studyprovides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Zydelig (idelalisib)Mechanism of Action: PI3K delta inhibitor, which helps to inhibit the […]

The Eliquis Resubmission Journey: Navigating the Path to FDA Approval

FDA CRL Wordcloud9

Hello Regulatory Scientists, Today, let’s explore the journey of Eliquis (apixaban) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Eliquis (apixaban) Mechanism of Action: Factor Xa inhibitor, which helps to […]

The Farxiga Resubmission Journey: Turning an FDA CRL into Success

darkhorse consulting

Hello Regulatory Scientists, Today, let’s explore the journey of Farxiga (dapagliflozin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case provides invaluable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Farxiga (dapagliflozin) Mechanism of Action: Sodium-glucose co-transporter 2 (SGLT2) inhibitor Indication: Type […]

Turning Setbacks into Success: The Eylea Resubmission Journey

FDA CRL Wordcloud2

Hello Regulatory Scientists, Let’s delve into the journey of Eylea (aflibercept) from receiving an FDA Complete Response Letter (CRL) to its eventual approval. Understanding this case provides valuable insights and lessons for those developing new drugs today. Regulatory History and Initial Submission Drug: Eylea (aflibercept) Mechanism of Action: Vascular Endothelial Growth Factor (VEGF) inhibitor Indication: […]

The Qsymia Resubmission Journey: Overcoming an FDA Complete Response Letter

Hello Regulatory Scientists, Today, let’s dive into the journey of Mayzent (siponimod) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Mayzent (siponimod) Mechanism of Action: Sphingosine-1-phosphate receptor modulator, which helps reduce the number of lymphocytes that can reach the central nervous system Indication: Treatment of relapsing forms of multiple sclerosis (MS) Initial Submission Date: February 2018 The Complete Response Letter (CRL) CRL Date: June 2018 CRL Concerns: Clinical Data Requirements: The FDA requested more detailed analyses of the clinical data to better understand the efficacy of the drug across different patient subgroups. Safety Profile: Concerns related to the drug’s long-term safety profile, including cardiovascular risks and potential adverse effects on liver function. Manufacturing Process: Issues related to the consistency and quality of the drug’s manufacturing process. Resubmission Strategy Novartis, the company behind Mayzent, implemented a comprehensive strategy to address the FDA’s concerns: Extended Data Analysis: Conducted additional analyses of the clinical trial data to provide a clearer picture of the drug’s efficacy across various patient subgroups. Enhanced Safety Monitoring: Provided additional data on the long-term safety profile, focusing on cardiovascular health and liver function. Improved Manufacturing Processes: Implemented improvements in the manufacturing process to ensure consistency and quality. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. Resubmission Date: October 2018 Outcome Approval Date: March 2019 Mayzent was approved for the treatment of relapsing forms of multiple sclerosis, providing a new option for patients with this condition. Lessons Learned The journey of Mayzent from CRL to approval highlights several key lessons for drug developers: Thorough Data Analysis: Providing detailed and comprehensive data analyses is crucial to demonstrate a drug’s efficacy across different patient subgroups. Robust Safety Monitoring: Ensuring a thorough understanding and communication of the drug’s long-term safety profile can help mitigate regulatory concerns. Improved Manufacturing Standards: Ensuring the quality and consistency of the manufacturing process is essential for regulatory approval. Effective Use of Advisory Committees: Leveraging advisory committees can provide valuable feedback and support the resubmission process. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. Relevance for Current Drug Developers For companies developing drugs today, the Mayzent case underscores the importance of strategic planning and meticulous data analysis in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including clinical data and manufacturing processes, meet FDA standards. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. By learning from the Mayzent resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. Stay diligent and strategic, CERES Regulatory Services

Hello Regulatory Scientists, Today, let’s explore the journey of Qsymia (phentermine and topiramate extended-release) from receiving an FDA Complete Response Letter (CRL) to gaining approval. This case offers valuable insights and lessons that can be applied by companies developing new drugs today. Regulatory History and Initial Submission Drug: Qsymia (phentermine and topiramate extended-release) Mechanism of […]

Navigating FDA Accelerated Approval Pathways: A Story of Speeding to Success with Fast Track, Breakthrough Therapy and Priority Review Desigations

The FDA Srug Approval Process from nonclinical to clinical development and Phase 1 to Phase 3 Studies leading to approval.

Hello Regulatory Scientists, Let’s take a journey through the world of Accelerated Approval Pathways with Dr. Mike, a passionate regulatory scientist, determined to get his groundbreaking therapy to patients as quickly as possible. In this story, we’ll explore how Dr. Mike leverages Fast Track, Breakthrough Therapy, and Priority Review designations to speed up the approval […]